P. berghei complete liver stage compound screening and profiling

Primary screening to take place at Calibr. Assays will be run in 1536wp format, using vital luciferase readouts at 48 and 72 hours post-infection (hpi) to detect compounds with activity throughout the P. berghei liver stage. Primary screening will be single concentration; the concentration to be screened will be determined based on library-specific recommendations, and approved by MMV. After triage, all potential actives (anticipated <1000) will be subjected to full phenotypic profiling at UTSA, again single concentration, according to our standard workflow incorporating a luminescence-based parasite biomass readout and high content imaging readouts of parasite maturation and terminal phenotype. Phenotypic profiles for each compound will be compared against those from the MMV validation set. Compounds of interest with confirmed activity will be assessed in 8 point concentration-response (3-fold serial dilution from 10,000 nM to 4.6 nM).